Chemours (CC) has just priced a larger than initially planned private offering of US$700 million in new 7.875% senior notes due 2034. This refinancing move directly targets its nearer term bond maturities.
See our latest analysis for Chemours.
At a share price of US$16.41, Chemours has recently seen a 10.0% 7 day share price decline and an 8.5% 30 day share price decline, although its 90 day share price return of 29.2% and 1 year total shareholder return of 19.3% suggest improving sentiment compared with the 3 and 5 year total shareholder return figures. The upsized bond deal, recent conference appearances, and its partnership around Opteon immersion cooling all contribute to how investors are weighing growth potential against balance sheet and refinancing risk.
If this refinancing story has you thinking about where capital intensive trends meet future tech, it could be worth scanning 24 power grid technology and infrastructure stocks as a way to spot other potential ideas.
With Chemours trading at US$16.41, sitting at a discount to analyst targets and with an indicated intrinsic discount, the question is simple: is this a mispriced turnaround story, or is the market already factoring in future growth?
Most Popular Narrative: 50% Overvalued
Compared with the narrative fair value of about $16.33, Chemours at $16.41 sits close to that estimate, yet the narrative still tags the shares as overvalued based on its inputs and assumptions.
Progress in resolving legacy PFAS litigation risk highlighted by the New Jersey settlement and insurance recoveries has significantly improved long term earnings visibility and reduced potential future cash outflows, removing a major overhang and enhancing free cash flow conversion.
Curious what earnings path and margin reset are baked into that valuation call? The narrative relies on a specific profit swing and a future earnings multiple that sits well below many peers. The full story connects those moving parts into one concise fair value case.
Result: Fair Value of $16.33 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still real tension here, with unresolved PFAS lawsuits and potential settlements, as well as any prolonged TiO2 or end market softness, both capable of upsetting that fair value story.
Find out about the key risks to this Chemours narrative.
Another View: Cash Flow Says Something Different
While the narrative fair value of about $16.33 suggests Chemours is overvalued at $16.41, our DCF model paints a very different picture, with a future cash flow value of $48.55. That is a wide gap. Which set of assumptions do you think is closer to how Chemours will actually perform?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
If this mix of caution and opportunity feels familiar, take a moment now to look through the numbers yourself and decide what really matters to you, then weigh up the balance of 3 key rewards and 2 important warning signs before you settle on your own view.
Looking for more investment ideas?
Before you move on, give yourself a better shot at finding the next opportunity by checking a few focused stock lists that match different goals and risk levels.
- Zero in on potential bargains by scanning companies our models flag as attractively priced with strong fundamentals through 50 high quality undervalued stocks tailored for value focused investors.
- Strengthen your income game by reviewing businesses that combine higher yields with resilience using our list of 16 dividend fortresses that can anchor a dividend focused portfolio.
- Protect your capital first by filtering for companies with robust finances and cleaner risk profiles using a 63 resilient stocks with low risk scores that highlights sturdier balance sheets.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com